Third-party tested for potency, purity, and quality
however, 'feeling cold' is not listed as a recognised adverse reaction in the UK Summary of Product Characteristics (SmPC) for semaglutide and should therefore be regarded as patient-reported rather than regulator-confirmed for this drug class
Week after week, I saw the scale slowly drop
Food and Drug Administration (FDA) (2017) Medullary thyroid carcinoma, an uncommon cause of thyroid nodules but an important cause of thyroid neoplasms, Mayo Clinic Proceedings (1992) Glucagon-like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus, JAMA Internal Medicine (2013) Semaglutide and cardiovascular complications in patient with type 2 diabetes mellitus, The New England Journal of Medicine (2016) Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases, JAMA Internal Medicine (2022) Diabetic retinopathy, Mayo Clinic (2023) Semaglutide, reduction in glycated hemoglobin and the risk of diabetic retinopathy, Diabetes, Obesity, and Metabolism (2018) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Please consult your physician or pharmacist or product package for more information